Monthly cumulative data tracks infants under eight months receiving at least one RSV monoclonal antibody dose across U.S. jurisdictions. Estimates derive from aggregate Immunization Information Systems (IIS) data submitted to the CDC, with reporting beginning April 1 of each season. National estimates are excluded as participation from all jurisdictions is not yet complete.
Use Cases
- Analyze trends in `Estimate` (coverage percent) over `Month` to assess the rollout speed of RSV antibody prophylaxis each `Season`.
- Compare `Numerator` (children receiving doses) against `Population` (eligible children) across different `Jurisdiction`s to identify areas with low coverage.
- Model jurisdictional `Estimate` variations using `Jurisdiction` and `Month` features to predict future immunization campaign performance.
- Track coverage within the specific `Age_group_label` (0-7 months) to evaluate the program's reach to the target infant population.
Strengths
- Data is updated monthly, providing current surveillance of a public health intervention.
- Includes key metrics `Numerator`, `Population`, and derived `Estimate` for direct coverage calculation.
- Covers multiple U.S. states, localities, and territories as reporting `Jurisdiction`s.
Limitations
- Row count and total data volume are unknown, limiting assessment of statistical power.
- National estimates are unavailable due to incomplete jurisdictional reporting to the CDC.
- Data is aggregated, preventing individual-level analysis of patient demographics or timing.
Provenance
- Source
- data.cdc.gov, sourced from U.S. jurisdictions' Immunization Information Systems (IIS).
- Collection Method
- Aggregate data submitted monthly by jurisdictions to the CDC.
- Time Range
- Cumulative from April 1 through the end of each reporting month, by season.
- Freshness
- Updated monthly; last platform update was 2026-03-20.
- Geography
- United States, reported by jurisdiction (states, some localities, and territories).